Clinical Trials Logo

Clinical Trial Summary

This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose- escalation study in otherwise healthy cat-, dust mite-, or Bermuda grass-allergic male and female subjects. There will be five dosing cohorts (0.1, 0.3, 1.0, 3.0 and 10.0 mg/kg), with eight subjects in each cohort, randomized to either epsi-gam (6 subjects) or placebo (2 subjects) for a total of 40 subjects. The first cohort will receive the starting dose of 0.1 mg/kg epsi-gam or placebo and subsequent cohorts will be recruited sequentially to receive escalating doses of epsi-gam or placebo.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02559258
Study type Interventional
Source Tunitas Therapeutics, Inc.
Contact
Status Terminated
Phase Phase 1
Start date August 2015
Completion date May 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06260956 - Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg N/A
Completed NCT03763630 - MAPS & ITEC Cohorts: 6-8 Years Follow-up Phase 2
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Completed NCT04916145 - An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy Adults N/A
Recruiting NCT05394363 - Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Recruiting NCT05323357 - Bern Human Organoid-Study to Study Host-microbe Interaction
Recruiting NCT04438629 - Evaluation of Immune Response in COVID-19 Patients
Recruiting NCT04751760 - Feasibility Study of a New Immunoglobulin E (IgE) Assay Method